AmpliTech Group cuts Titan Crest price to $7M, targets FY27 EBITDA
AmpliTech Group (NASDAQ: AMPG) cut the Titan Crest asset purchase price by $1 million to $7 million and said it has zero long-term debt and about $17 million in current order backlog. For Q2 2026 it reported a net loss of $3.09 million (12 cents/share) on $8.07 million revenue. It targets positive EBITDA in FY2027.
How this was made
The 30-second read
Why it matters
The article combines (1) a revised $7M Titan Crest acquisition price and (2) a profitability roadmap to positive FY27 EBITDA, but also reports a wider-than-expected Q2 net loss driven by doubled R&D and higher SG&A.
Market read
Traders get a near-term catalyst from the Q2 earnings miss and a medium-term catalyst from the FY27 EBITDA target and acquisition economics change.
What to watch
Order timing variability from customer deployments could delay shipments into 2H26 or 2027, pushing EBITDA conversion out even if gross margins are improving.
Background
AmpliTech is scaling 5G ORAN and related microwave/semiconductor programs and has been investing heavily to commercialize after an initial market-entry phase.
Ticker impact
AmpliTech cut the Titan Crest asset purchase price to $7M and guided to positive FY27 EBITDA, while Q2 losses widened despite revenue beat.
Likely choppy trading: upside from FY27 EBITDA guidance and stronger gross margin, downside from the immediate profitability miss and elevated investment pace.
The article provides both a fresh balance-sheet/acquisition update and a new profitability outlook, but also reports a same-period earnings deterioration that can dominate sentiment until investors see execution on margin-to-EBITDA conversion.
Market effects
Signals ORAN and related 5G infrastructure vendors may be in a margin transition phase where gross profit improves before EBITDA turns.
No clear regional read-through beyond North America and international customer discussions.
Limited; the story is company-specific with no broader industry policy or macro catalyst.
Counterpoint
The FY27 EBITDA path may be optimistic if higher R&D intensity persists longer than management expects, especially given the Q2 net loss widening.
Key entities
- public_companyAmpliTech Group, Inc.
NASDAQ-listed ORAN and microwave/semiconductor-focused company issuing revised acquisition economics and FY27 EBITDA guidance.
- private_companyTitan Crest, LLC
Counterparty in the asset acquisition whose purchase price was reduced to $7M via an amendment.
- financial_institutionMaxim Group LLC
Broker/dealer whose equity distribution agreement was terminated, alongside authorization of a $10M repurchase program.
